Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia
- VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for treatment of FTD(GRN)
- Data demonstrate excellent safety, tolerability profile, dose-proportionality and target engagement with elevations in progranulin in both plasma and CNS
- CTA filed for Phase IIa study, first dose targeted for Q4 2024
Copenhagen, Denmark, 04 September 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces the successful completion of the Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)).
